Back to top

MTN-029/IPM 039

Protocol Chair(s)
Beigi, Richard (Protocol Co-Chair)
Noguchi, Lisa (Protocol Chair)
MTN-029 is a Phase I study that seeks to determine whether a vaginal ring containing the antiretroviral (ARV) drug dapivirine is a safe method for protecting against HIV infection when used by lactating women by assessing whether and how dapivirine is expressed in breast milk.

MTN-030/IPM 041

Protocol Chair(s)
Achilles, Sharon (Protocol Chair)
Chen, Beatrice (Protocol Co-Chair)

MTN-030/IPM 041 was a multi-site, randomized, double blind Phase 1 trial. The study assessed pharmacokinetics and safety of two silicone elastomer vaginal matrix rings containing either 200 mg of dapivirine alone or 200 mg of dapivirine and 320 mg of levonorgestrel. The MTN-030/IPM 041 study population consisted of healthy, HIV-uninfected, non-pregnant women between 18-45 years of age.

MTN-028

Protocol Chair(s)
Liu, Albert (Protocol Chair)
MTN-028 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of vaginal rings (VRs) containing varying dose strengths of the antiretroviral (ARV) drugs Vicriviroc (MK-4176) and MK-2048. The study will enroll approximately 18 women at one U.S. site beginning in mid to late 2015 and will take approximately 6-9 months to conduct.

MTN-027

Protocol Chair(s)
Hoesley, Craig (Protocol Chair)
MTN-027 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of vaginal rings (VRs) containing (1) the antiretroviral (ARV) drug Vicriviroc (MK-4176); (2) the ARV drug MK-2048; or (3) the two ARV drugs in combination. The study will enroll pproximately 48 women at two U.S. sites in mid to late 2015 and will take approximately 6-9 months to conduct.

MTN-026

Protocol Chair(s)
Cranston, Ross (Protocol Chair)
MTN-026 is a Phase I study that seeks to evaluate the safety and systemic and local pharmacokinetics (PK) of a rectal gel containing the antiretroviral (ARV) drug dapivirine. The study will enroll approximately 24 men and women at two U.S. sites and take approximately 9-12 months to conduct.